hengrui glp-1 💊 ORAL UPDATE 💊 Kailera/Hengrui's HRS-7535 showed 9.8% weight loss in a 44-week Phase 3 trial in China. 🇨🇳 While effective and free of hepatotoxicity, high rates of nausea (70%) and The Race Is On: Winning

All FDA-approved GLP-1 medications carry important safety information, including contraindications for patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

Poor diet choices can also make side effects like nausea or constipation worse

Suddenly stopping these medications may lead to changes in blood sugar levels and appetite regulation

doi: 10.1080/00325481.2020.1798099 207 PiccoliGFMesquitaLASteinCAzizMZoldanMDegobiNAHet al

Results from clinical trials suggest that such drugs could have potential for the treatment of asthma, which is one of the most chronic inflammatory pulmonary diseases in the world and often linked to both type 2 diabetes and obesity (Wu, Stokes Peebles)